Glurenorm (Gliquidone)

Glurenorm is indicated for the management of type 2 diabetes mellitus in adults when diet, exercise, and other oral agents are insufficient to achieve glycemic control.

• Used as monotherapy in patients newly diagnosed with type 2 diabetes who do not require insulin.
• Added to metformin or other oral antidiabetic agents when additional glucose lowering is needed.
• Employed in combination therapy to improve post‑prandial glucose excursions.
• Considered when patients have contraindications to newer drug classes such as DPP‑4 inhibitors or SGLT2 inhibitors.
• May be prescribed in patients with stable renal function who can tolerate sulfonylureas.

The safety profile of Glurenorm reflects the typical effects of sulfonylurea agents, ranging from mild, frequently reported events to rare but serious reactions.

Common

• Mild hypoglycemia, especially if meals are skipped.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Allergic reactions such as rash, pruritus, or angio‑edema.
• Hematologic abnormalities like leukopenia or thrombocytopenia.

Before initiating Glurenorm, clinicians should evaluate several clinical factors to minimize risks and ensure appropriate use.

• Assess renal and hepatic function; dose adjustment may be required in impairment.
• Review history of cardiovascular disease, as sulfonylureas can affect cardiac ischemic preconditioning.
• Monitor for signs of hypoglycemia, particularly in elderly patients or those with irregular eating patterns.
• Use caution in patients with a known allergy to sulfonylureas or related compounds.
• Evaluate concomitant use of insulin or other hypoglycemic agents to avoid excessive glucose lowering.
• Consider pregnancy and lactation status; Glurenorm is generally not recommended during these periods.

Glurenorm can interact with several medicines, altering its efficacy or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause profound hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise gliquidone plasma levels.
• MAO‑B inhibitors, which may potentiate hypoglycemic effects.
• High‑dose aspirin or NSAIDs that can mask hypoglycemia symptoms.

Use with caution

• Beta‑blockers, which may blunt the typical warning signs of hypoglycemia.
• Thiazide diuretics, as they can affect glucose metabolism.
• Oral contraceptives, which may slightly increase blood glucose levels.